Comprehensive Evaluation of OATP ‐ and BCRP ‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
Clinical Pharmacology & Therapeutics · 2024-10 · 116 (4) · 1013-1022
DOI: 10.1002/cpt.3329 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 11.06.2024. Verfasst von Sejung Hwang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Methotrexate, Drug Interactions, Cross-Over Studies, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea (NRF), Seoul National University Bundang Hospital (SNUBH).
Abstract (Originalsprache)
Methotrexate (MTX) is an antifolate agent widely used for treating conditions such as rheumatoid arthritis and hematologic cancer. This study aimed to quantitatively interpret the drug–drug interactions (DDIs) of MTX mediated by drug transporters using physiologically‐based pharmacokinetic (PBPK) modeling. An open‐label, randomized, 4‐treatment, 6‐sequence, 4‐period crossover study was conducted to investigate the effects of rifampicin (RFP), an inhibitor of organic anionic transporting peptides (OATP) 1B1/3, and febuxostat (FBX), an inhibitor of breast cancer resistance protein (BCRP), on the pharmacokinetics of MTX in healthy volunteers. PBPK models of MTX, RFP, and FBX were developed based on in vitro and in vivo data, and the performance of the simulation results for final PBPK models was validated in a clinical study. In the clinical study, when MTX was co‐administered with RFP or FBX, systemic exposure of MTX increased by 33% and 17%, respectively, compared with that when MTX was administered alone. When MTX was co‐administered with RFP and FBX, systemic exposure increased by 52% compared with that when MTX was administered alone. The final PBPK model showed a good prediction performance for the observed clinical data. The PBPK model of MTX was well developed in this study and can be used as a potential mechanistic model to predict and evaluate drug transporter‐mediated DDIs of MTX with other drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, Korea.
- Kidney Research Institute, Seoul National University Medical Research Center, Seoul, Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Korea.
- Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Korea.
ORCID-Profile: Sejung Hwang, Yeonseo Jang, Joo-Youn Cho, Seonghae Yoon, Jae-Yong Chung
Förderung
- National Research Foundation of Korea (NRF)
- Seoul National University Bundang Hospital (SNUBH)
Zitieren
APA
Hwang, S., Lee, Y., Jang, Y., Cho, J. Y., Yoon, S., & Chung, J. Y. (2024). Comprehensive Evaluation of OATP ‐ and BCRP ‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics, 116(4), 1013-1022. https://doi.org/10.1002/cpt.3329
Vancouver
Hwang S, Lee Y, Jang Y, Cho JY, Yoon S, Chung JY. Comprehensive Evaluation of OATP ‐ and BCRP ‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 2024;116(4):1013-1022. doi:10.1002/cpt.3329
BibTeX
@article{Hwang2024,
author = {Hwang, Sejung and Lee, Yujin and Jang, Yeonseo and Cho, Joo-Youn and Yoon, Seonghae and Chung, Jae-Yong},
title = {Comprehensive Evaluation of OATP ‐ and BCRP ‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {116},
number = {4},
pages = {1013--1022},
doi = {10.1002/cpt.3329}
}
EUVIMED